Lupin has entered into a long term strategic partnership with Merck Serono, the Biopharmaceutical division of Merck. Lupin will support Merck Serono in the implementation of the company's General Medicines portfolio expansion initiative in emerging markets. The agreement builds on an established working relationship between the two companies, and could add up to 20 new products to the current portfolio. The first launches are expected in 2016.
 
Commenting on the same, Sarabjit Kour Nangra, VP Research, IT, Angel Broking, said, ''Through this partnership, Merck Serono will expand its overall portfolio in core therapeutic areas of Merck Serono's General Medicine & Endocrinology franchise in selected countries in Latin America, Asia, Central Eastern Europe, and Africa. The partnership covers major markets such as Brazil, Mexico, Indonesia, Philippines alongside several countries in Africa and Central Eastern Europe as well as other countries in emerging markets, focusing on cardiovascular and diabetes diseases. In Africa, medicines will also be supplied for additional therapeutic areas, reflecting local healthcare needs such as availability of antibiotics.
 
With the alliance, Lupin will expand its presence in these markets with fordable player like Merck Serono, which grosses sales of Euro 1.8 billion (in 2013) in emerging markets. The deal will start reflecting from FY2017 and hence do not change our estimates and remain neutral on stock on back of valuations.''

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.